KR20170109972A - Design, synthesis, and applications of upconversion nanoparticles using the first principles - Google Patents

Abstract

The present invention relates to a method for producing a compound of formula (I), which comprises at least one host selected from LiYF ₄ , NaY, NaYF ₄ , NaGdF ₄ and CaF ₃ ; At least one sensitizer selected from Sm ^{3 +} , Nd ^{3 +} , Dy ^{3 +} , Ho ^{3 +} and Yb ^{3 +} doped to the host; And at least one activator selected from Er ^{3 +} , Ho ^{3 +} , Tm ^{3 +} and Eu ^{3 +} doped to the host. The upconverted nanoparticles of the present invention can be designed using first-principles calculations to absorb near-infrared wavelengths with stability. It is also possible to use such up-converted nanoparticles in combination with hyaluronic acid to utilize them in various places in the body having hyaluronic acid receptors, to provide hyaluronic acid-upturned nanoparticles capable of specifically targeting and maintaining body maintenance period and biocompatibility Lt; / RTI >

Description

{DESIGN, SYNTHESIS, AND APPLICATIONS OF UPCONVERSION NANOPARTICLES USING THE FIRST PRINCIPLES}

The present invention relates to an upconverted nanoparticle, a hyaluronic acid-upconverted nanoparticle conjugate and a method for producing the same, and more particularly, to a first principles calculation designed to absorb a near-infrared wavelength using a first principle calculation Up-converted nano-particles, hyaluronic acid-up-converted nano-particle conjugates, and a method for producing the same.

First principles study is a computational method based on quantum mechanics, in which the properties of a material are calculated without the help of other empirical values except for the location and kind of atoms. Because of this property, realistic physical quantities can be calculated, and it is not only easy to directly compare with experimental results, but also has a prediction ability. Quantum mechanics has been established in the 20th century, and it is known that the behavior of electrons can be calculated by Schrodinger's wave equation by a number of experiments. However, in order to describe a large number of interacting electrons in a solid, this method has its limitations and its practical application is limited to calculating the state of an independent atom or calculating the quantum state of a simple molecule composed of several atoms. In order to describe the state of a solid, a density functional theory, which describes the behavior of quasiparticles that do not interact, is mainly used instead of calculating the multibody Schrodinger wave equation of interacting electrons . This method has been proven to be capable of accurately describing the properties of many common solids and has predictability, but has the disadvantage of failing to adequately describe localized electrons.

 Energy transfer upconversion (ETU) requires information on atomic multiplet energies and state functions to properly simulate critical energy scales. The distribution characteristics of these energy levels are altered by various structural factors such as atomic species, electron-electron interaction screening, and crystal field by surrounding ligand atoms. The density function theory is a good way to describe well.

Upconverting nanoparticles can be designed using the above principle of principle calculation. The upconverting nanoparticles are nano-sized particles that can be synthesized by doping a host with trivalent lanthanide ions having 4f orbitals, and ff Based on the ETU phenomenon between orbitals, it is a nanomaterial that absorbs light of a long wavelength and emits light of a short wavelength. Conventional upconverting particles use a variety of lanthanide ions as sensitizers to transfer energy to the various activator doping ions in the triplet and quadruplet stages, It is based on the mechanism system.

The long wavelength of the near infrared region is known to be transmitted to a depth of about 3.5 cm on the basis of 808 nm, and its depth increases with increasing wavelength. However, as the water present in the tissues and blood of the body absorbs light of a long wavelength, there is a problem that the depth of laser light actually penetrates through the skin is gradually decreased after 808 nm. However, as the wavelength becomes longer, the degree of skin invasion according to the intensity of the laser decreases and the stability is increased accordingly. In addition, with the approval of the KFDA, Lutronics and other medical device companies developed and produced laser medical devices used for skin treatment and eye disease treatment with Nd: YAG laser (Neodymium aluminum garnet laser) emitting 1,064 nm near-infrared It is. Therefore, it is necessary to develop up-conversion nanoparticles capable of absorbing and utilizing near-infrared light of 1,064 nm.

It is an object of the present invention to provide up-conversion nanoparticles designed to absorb stable near-infrared wavelengths using first-principle calculations in order to solve the above problems.

It is also possible to use such up-converted nanoparticles in combination with hyaluronic acid to utilize them in various places in the body having hyaluronic acid receptors, to provide hyaluronic acid-upturned nanoparticles capable of specifically targeting and maintaining body maintenance period and biocompatibility Gt;

According to an aspect of the present invention,

At least one host selected from LiYF ₄ , NaY, NaYF ₄ , NaGdF ₄ and CaF ₃ ; At least one sensitizer selected from Sm ^{3 +} , Nd ^{3 +} , Dy ^{3 +} , Ho ^{3 +} and Yb ^{3 +} doped in the host; And at least one activator selected from Er ^{3 +} , Ho ^{3 +} , Tm ^{3 +} and Eu ^{3 +} doped to the host.

The upconverted nanoparticles may be determined by calculating the optimal chemical composition of the lanthanide ion-doped upconverted nanoparticles that absorb at least one wavelength selected from 808, 980, and 1,064 nm through first principle calculation.

The upconverted nanoparticles may absorb at least one wavelength selected from 808, 980 and 1,064 nm to emit visible light.

The molar ratio of the sensitizer to the host may be 80:10 to 80:60.

According to another aspect of the present invention,

The upconverted nanoparticle; And hyaluronic acid or derivatives thereof bound to the upconverted nanoparticles. The hyaluronic acid-upturned nanoparticle conjugate is provided.

The hyaluronic acid-upturned nanoparticle conjugate may further comprise a photosensitizer.

The photosensitizer may be at least one selected from chlorine e6 (Ce6), porphyrin-based photosensitizer and nonporphyrin-based photosensitizer.

The photosensitizer may be bound to the up-converted nanoparticle in an amount of 1 to 2 parts by weight based on 1 part by weight of the up-converted nanoparticles.

The hyaluronic acid derivative may be hyaluronic acid substituted with a cystamine having the structure of the following formula (1).

[Chemical Formula 1]

In Formula 1,

x and y are each independently an integer selected from 16 to 2,500.

The cystamine may be substituted with the substitution ratio of 10 to 21% with respect to the hyaluronic acid.

The weight ratio of the upconverted nanoparticles to hyaluronic acid or derivatives thereof may be from 1: 1 to 4: 1.

According to another aspect of the present invention,

(1) preparing a solution by mixing a host precursor, a sensitizer, an activator, and a solvent; And (2) heat-treating the solution to produce up-converted nanoparticles.

Wherein the host precursor is selected from the group consisting of YCl ₃ .H ₂ O, YbCl ₃ .H ₂ O, SmCl ₃ .H ₂ O, NdCl ₃ .H ₂ O, GdCl ₃ .H ₂ O, Ca (CF ₃ COO) ₂ , CF ₃ COONa 1 selected from Y (CF ₃ COO) ₃ , Yb (CF ₃ COO) ₃ , Gd (CF ₃ COO) ₃ , Sm (CF ₃ COO) _{3 ,} Nd (CF ₃ COO) _3, NH ₄ F, Or more species.

The solvent may include octadecene-1.

The solution may further comprise at least one selected from oleic acid and oleylamine.

The heat treatment may be performed at 250 to 400 ° C.

According to another aspect of the present invention,

(a) binding the hyaluronic acid or derivatives thereof to the up-converted nanoparticles.

Wherein the binding step comprises the steps of (a ') mixing or dissolving the hyaluronic acid or derivative thereof and the up-converted nanoparticles, and then adding 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride 1- (3-Dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride, EDC).

And (a-1) modifying the surface of the up-converted nanoparticle before the step (a ').

The surface of the upconverted nanoparticles may be treated with one or more selected from the group consisting of polyallylamine, polymethylmethacrylate (PMMA), 3-aminopropyltriethoxysilane (APTES), tetraethylorthosilicate (TEOS) Dihydroxyphenylalanine (DOPA), and cetyltrimethylammonium bromide (CTAB).

According to another aspect of the present invention,

There is provided a composition for optical genetics applicable to photogenetics comprising the hyaluronic acid-upturned nanoparticle conjugate as an active ingredient.

The photomultiplier composition may be used to control neuronal cells using one or more wavelength lasers selected from 808, 980 and 1,064 nm.

According to another aspect of the present invention,

There is provided a composition for photodynamic therapy comprising the hyaluronic acid-up-converted nanoparticle conjugate as an active ingredient.

The composition for photodynamic therapy can be used for treating skin diseases or cancer.

The composition for photodynamic therapy may be a patch, a depot or an external preparation.

According to another aspect of the present invention,

There is provided a non-invasive in-vivo light source material delivery system through transdermal delivery of the hyaluronic acid-upturned nanoparticle conjugate.

The non-invasive in-vivo light source material delivery system can be used for the treatment and diagnosis of cancer, skin diseases and ocular diseases.

The non-invasive in-vivo light source material delivery system can be used for fluorescent tattoos.

The upconverted nanoparticles of the present invention can be designed using first-principles calculations to absorb near-infrared wavelengths with stability.

It is also possible to use such up-converted nanoparticles in combination with hyaluronic acid to utilize them in various places in the body having hyaluronic acid receptors, to provide hyaluronic acid-upturned nanoparticles capable of specifically targeting and maintaining body maintenance period and biocompatibility Lt; / RTI >

BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a schematic view schematically showing a structure and a manufacturing method of a hyaluronic acid-upturned nanoparticle conjugate according to the present invention, which additionally comprises the upconverted nanoparticle, the hyaluronic acid-upconverted nanoparticle conjugate and the photosensitizer .
Fig. 2 shows changes in the atomic multiple energy of the upconverted nanoparticles (Li ₃ F ₄ doped Sm ^{3 +} ) prepared according to Example 1. Fig.
FIG. 3 shows changes in atomic multiplex energy of upconverted nanoparticles prepared according to Example 2 and upconverted nanoparticles doped with Er ^{3 +} in CaF ₃ .
FIG. 4 shows the results of transdermal transfection of the hyaluronic acid-upturned nanoparticle conjugate prepared in Example 2 and fluorescence of the hyaluronic acid-upturned nanoparticle conjugate delivered in vivo to the abdomen of a mouse.
FIG. 5 is a graph showing the results of measurement of up-converted nanoparticles prepared in Example 2, silica-coated up-converted nanoparticles prepared in Example 4, and hyaluronic acid- It is the result of analysis through electron microscope.
FIG. 6 is a graph showing changes in fluorescence intensity and fluorescence efficiency of upconverted nanoparticles prepared according to Example 2. FIG.
FIG. 7 shows the cytotoxicity of the hyaluronic acid-upturned nanoparticle conjugate prepared in Example 4 and the hyaluronic acid-organic carbon dot conjugate prepared in Comparative Example 1 through MTT assay.
FIG. 8 is a result of transdermal delivery of the hyaluronic acid-uptake-converted nanoparticle conjugate and distilled water prepared according to Example 4 to the abdomen of a rat, followed by laser irradiation and observation under a two-photon microscope.

Hereinafter, embodiments of the present invention will be described in detail with reference to the accompanying drawings so that those skilled in the art can easily carry out the present invention.

However, the following description does not limit the present invention to specific embodiments. In the following description of the present invention, detailed description of related arts will be omitted if it is determined that the gist of the present invention may be blurred .

The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. The singular expressions include plural expressions unless the context clearly dictates otherwise. In the present application, the terms "comprises ", or" having ", and the like, specify that the presence of stated features, integers, steps, operations, elements, or combinations thereof, But do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, or combinations thereof.

Hereinafter, the up-converted nanoparticles of the present invention will be described in detail. However, it should be understood that the present invention is not limited thereto, and the present invention is only defined by the scope of the following claims.

1 shows a hyaluronic acid-upturned nanoparticle conjugate (HA-UCNP-Ce6 (SEQ ID NO: 1)) which further comprises the upconverted nanoparticles (UCNP), hyaluronic acid-upconverted nanoparticle conjugate (HA- Up-converted nanoparticle conjugate (HA-UCNP-Ce6) further comprising the structure of the hyaluronic acid-upturned nanoparticle conjugate (HA-UCNP) and the photosensitizer. Here, hyaluronic acid (Hyaluronic aicd-cucurbitrile [6]), photosensitizer (Ce6), and poly (allylamine) are limited, but the present invention is not limited thereto.

The upconverted nanoparticles of the present invention include at least one host selected from LiYF ₄ , NaY, NaYF ₄ , NaGdF ₄ and CaF ₃ ; At least one sensitizer selected from Sm ^{3 +} , Nd ^{3 +} , Dy ^{3 +} , Ho ^{3 +} and Yb ^{3 +} doped in the host; And one or more activators selected from Er ^{3 +} , Ho ^{3 +} , Tm ^{3 +} and Eu ^{3 +} doped to the host.

The upconverted nanoparticles can be obtained by increasing the efficiency of upconverting nanoparticles absorbing the existing 808 nm and 980 nm through the first principle calculation and by using the optimal chemistry of the lanthanide ion-doped upconverted nanoparticles absorbing the new 1,064 nm wavelength The host and the sensitizer can be determined by predicting the multiple antiferromagnetic energy levels of the various lanthanide ions through first principle calculation. Preferably, Sm ^{3 +} ions can be derived from the highest efficiency enhancer that absorbs the 1,064 nm wavelength. Specifically, the multiple anti-energy levels of the doping ions such as Sm ^{3 +} , Dy ^{3 +} , and Ho ^{3 +} due to the interaction of the up-converted particles with the host can be calculated using the first principle. Density functional theory is used to obtain structural information of doped trivalent lanthanide ions and to calculate the transition between atomic multiple energy and energy levels of lanthanide ions using the extracted parameters. Up-conversion materials can be theoretically designed and synthesized experimentally by obtaining emission spectra.

To finely calculate the atomic energy level, Hamiltonian can be diagonalized as shown in Equation 1 below.

[Formula 1]

H _{el -el} is a _term by electron-electron interaction, H _SOC is a term by spin-orbit interaction, and H _CEF is a term representing a crystal field.

The absorption spectrum is determined by the transition between the atomic energy levels, and the distribution of these energy levels is strongly dependent on the atom type of the sensitizer, and Sm ^{3 +} ions have energy levels capable of absorbing near infrared rays at 1,064 nm Can be derived from the existing experiments and atomic multiple energy calculation. The distribution of atomic energy levels also depends on the crystal field, which varies with the type of host and the location of the doped atoms.

Accordingly, it may be preferable to design the constituent components of the up-converted particles by selecting Sm ^{3 +} having the highest absorption intensity among the lanthanide ions having the energy level absorbing the near-infrared ray of 1,064 nm, which has been proved as stable.

The upconverted nanoparticles may absorb at least one wavelength selected from 808, 980 and 1,064 nm to emit visible light.

The molar ratio of the sensitizer to the host may be 80:10 to 80:60, preferably 80:10 to 80:30, and more preferably 80:18 to 80:25.

Hereinafter, the hyaluronic acid-up-converted nanoparticle conjugate of the present invention will be described.

In the present specification, the bond may be a chemical bond or a physical bond, preferably a chemical bond, specifically, a covalent bond, an ionic bond or a coordinate bond, preferably a covalent bond.

The hyaluronic acid-upturned nanoparticle conjugate of the present invention may comprise hyaluronic acid or derivatives thereof bound to the upconverted nanoparticles and the upconverted nanoparticles.

The up-converted nanoparticles can be utilized in various places in the body where hyaluronic acid receptors are present by interposing a biocompatible supramolecular hyaluronic acid on the surface by covalent bonding. In particular, it is possible to selectively and specifically target the inside of the skin and eyeball in which a large amount of hyaluronic acid receptor is present, and it is possible to increase the duration of the body and the biocompatibility.

There is no limitation on the molecular weight of the hyaluronic acid usable in the present invention, but it may be preferable that the weight average molecular weight range is 10,000 to 1,000,000. When the molecular weight of the hyaluronic acid is 10,000 or less, the ability to maintain the physiological stability of the up-converted particles is deteriorated, and when the molecular weight is 1,000,000 or more, the overall particle size becomes too large, which may be undesirable.

The hyaluronic acid-upturned nanoparticle conjugate may further comprise a photosensitizer.

The photosensitizer may be chlorine e6 (Ce6), porphyrin-based photosensitizer, nonporphyrin-based photosensitizer, and preferably chlorine e6.

The photosensitizer may be combined with 1 to 3 parts by weight, preferably 1 to 2 parts by weight, more preferably 2 parts by weight based on 1 part by weight of the up-converted nanoparticles.

When the functional group is a carboxylic acid, the porphyrin-based photo-sensitizer reacts with the amino group of the up-converted nanoparticle to form an amide bond. Otherwise, the up-converted nanoparticle forms a micelle, It can be delivered to the body.

The hyaluronic acid derivative may be hyaluronic acid substituted with a cystamine having the structure of the following formula (1).

[Chemical Formula 1]

In Formula 1,

x and y are each independently an integer selected from 16 to 2,500.

In the above formula (1), x and y may be determined according to the substitution ratio. For example, when the substitution rates are 30%, 20%, and 10%, respectively, x: y may be an integer existing in a ratio of 7: 3, 8: 2, 9: 1.

The cystamine may be substituted at a substitution rate of 10 to 21% relative to the hyaluronic acid, preferably 12 to 19%, more preferably 14 to 16%.

The weight ratio of the upconverted nanoparticles to hyaluronic acid or a derivative thereof may be from 1: 1 to 4: 1, preferably from 2: 1 to 4: 1, more preferably from 3: 1 to 4: 1.

Hereinafter, the method for producing the up-converted nanoparticles of the present invention will be described.

First, a host precursor, a sensitizer, an activator, and a solvent are mixed to prepare a solution (Step 1).

The host precursor may be selected from the group consisting of YCl ₃ .H ₂ O, YbCl ₃ .H ₂ O, SmCl ₃ .H ₂ O, NdCl ₃ .H ₂ O, GdCl ₃ .H ₂ O, Ca (CF ₃ COO) ₂ , CF ₃ COONa 1 selected from Y (CF ₃ COO) ₃ , Yb (CF ₃ COO) ₃ , Gd (CF ₃ COO) ₃ , Sm (CF ₃ COO) _{3 ,} Nd (CF ₃ COO) _3, NH ₄ F, And more preferably YCl ₃ .H ₂ O, YbCl ₃ .H ₂ O, NH ₄ F, NaOH.

The solvent may preferably be octadecene-1.

The solution may further contain oleic acid, oleylamine, and the like, preferably oleic acid. The oleic acid may serve to prevent passivating ligand-aggregation.

Next, the solution is heat-treated to produce up-converted nanoparticles (Step 2).

The heat treatment may be performed at 250 to 400 ° C, preferably 280 to 350 ° C, more preferably 290 to 330 ° C.

Hereinafter, a method for producing the hyaluronic acid-upturned nanoparticle conjugate of the present invention will be described.

First, the upconverted nanoparticles are bound to hyaluronic acid or derivatives thereof (step a).

Wherein the binding step comprises mixing or dissolving the hyaluronic acid or a derivative thereof and the up-converted nanoparticles with each other, and then adding 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (1- -Dimethylaminopropyl) -3-ethylcarbodiimide Hydrochloride, EDC) (step a ').

The step (a-1) may further include the step of modifying the surface of the up-converted nanoparticle before the step a '.

The surface of the upconverted nanoparticles may be treated with one or more selected from the group consisting of polyallylamine, polymethylmethacrylate (PMMA), 3-aminopropyltriethoxysilane (APTES), tetraethylorthosilicate (TEOS) Dihydroxyphenylalanine (DOPA), and cetyltrimethylammonium bromide (CTAB).

And removing the EDC after step a '.

Hereinafter, various forms of applying the hyaluronic acid-upturned nanoparticle conjugate of the present invention will be described.

There can be provided a composition for optical genetics applicable to photogenetics comprising the hyaluronic acid-upturned nanoparticle conjugate as an active ingredient.

The photomultiplier composition may be used to control neurons using lasers of 808, 980 and 1,064 nm.

A composition for photodynamic therapy comprising the hyaluronic acid-up-converted nanoparticle conjugate as an active ingredient may be provided.

The composition for photodynamic therapy can be used for treating skin diseases or cancer.

The composition for photodynamic therapy may be a patch, a depot or an external preparation.

A non-invasive in-vivo light source material delivery system through transdermal delivery of the hyaluronic acid-upturned nanoparticle conjugate can be provided.

The non-invasive in-vivo light source material delivery system can be used for the treatment and diagnosis of cancer, skin diseases and ocular diseases.

The non-invasive in-vivo light source material delivery system can be used for fluorescent tattoos.

[Example]

Hereinafter, preferred embodiments of the present invention will be described. However, this is for illustrative purposes only, and thus the scope of the present invention is not limited thereto.

Example 1: Preparation of upconverted nanoparticles

Addition of SmCl ₃ .H ₂ O, YCl ₃ .H ₂ O, YbCl ₃ .H ₂ O, NH ₄ F and NaOH to a solvent containing 15 ml of octadecene-1 and 6 ml of oleic acid under an inert gas atmosphere To prepare a mixed solution. The mixed solution was reacted at 150 for 30 minutes, then closed with nitrogen, and then heat-treated at 315 for 1 hour and 30 minutes. Next, the temperature was adjusted to room temperature, and then the reaction was terminated by adding ethanol to prepare the up-converted nanoparticles. The upconverted nanoparticles were separated using a centrifuge.

The change in atomic multiplex energy of the upconverted nanoparticles (Li ₃ F ₄ doped Sm ^{3 +} ) is shown in FIG.

Example 2: Preparation of upconverted nanoparticles

Instead of SmCl ₃ · H ₂ 0 was prepared in the mold and is converted nanoparticles in the same manner as in Example 1 except for using ErCl ₃ · H ₂ 0.

FIG. 3 shows changes in atomic multiplex energy of the upconverted nanoparticles and the upconverted nanoparticles doped with Er ^{3 +} in CaF ₃ .

Example 3: Preparation of hyaluronic acid-upturned nanoparticle conjugate

The up-converted nanoparticles prepared in Example 1 were subjected to a water-in-oil reverse method using 3-aminopropyltriethoxysilane (APTES) and tetraethly orthosilicate (TEOS) to replace oleic acid, which is a surface material of the up- After that, TEOS was injected at a rate of 1 ml / h using a syringe pump to coat silica with a thickness of 10 nm.

Next, the silica-coated up-converted nanoparticles and hyaluronic acid were dissolved in distilled water, and then 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride was used as a catalyst. -3-ethylcarbodiimide Hydrochloride, EDC) was added to prepare hyaluronic acid-upturned nanoparticle conjugate.

Example 4: Preparation of hyaluronic acid-upturned nanoparticle conjugate

The hyaluronic acid-upturned nanoparticle conjugate was prepared in the same manner as in Example 3, except that the upconverted nanoparticles prepared in Example 2 were used instead of the upconverted nanoparticles prepared in Example 1.

Example 5: Preparation of hyaluronic acid-upturned nanoparticle-photosensitizer conjugate

The hyaluronic acid-upturned nanoparticle conjugate prepared in Example 3 and chlorin e6 (Ce6) as a photosensitizer were dissolved in distilled water, and EDC was added as a catalyst to react them to form hyaluronic acid-upturned nanoparticle-photosensitive To prepare a conjugate.

Example 6: Preparation of hyaluronic acid-upturned nanoparticle-photosensitizer conjugate

Up-converted nanoparticle conjugate prepared according to Example 4 was used instead of the hyaluronic acid-up-converted nanoparticle conjugate prepared according to Example 3, except that the hyaluronic acid-up-converted nanoparticle conjugate prepared according to Example 4 was used in place of the hyaluronic acid- Nanoparticle-photo-sensitizer conjugate.

Comparative Example 1: Production of hyaluronic acid-organic carbon dot bonding

15 ml of octadecene-1 and hexadecylamine-1 were mixed to prepare a mixed solution, and the temperature was raised to 300 ° C in an argon environment. 1 g of citric acid was added to the mixed solution, followed by reaction for 3 hours to prepare an organic carbon point. The organic carbon point and the hyaluronic acid-tetrabutylammonium (TBA) derivative were dissolved in a dimethylsulfoxide (DMSO) solvent in a ratio of 4 weight parts of the organic carbon point with respect to 1 weight ratio of hyaluronic acid, and the mixture was mixed (Benzotriazol-1-yloxy ) tris (diimethylamino) phosphonium hexafluorophosphate (BOP) and N, N-diisopropylethylamine (DIPEA) catalyst at 37 ℃ for overnight. After the reaction, the mixture was purified through dialysis, and a hyaluronic acid-organic carbon dot conjugate was prepared by a lyophilization method.

[Test Example]

Test Example 1: Percutaneous delivery confirmation

The transdermal delivery of the hyaluronic acid-up-converted nanoparticle conjugate (UCNP @ SiO ₂ -HA) prepared according to Example 2 is schematically shown in FIG. 4 a, and the hyaluronic acid- Fig. 4 (b) shows the result of observing fluorescence by in vivo delivery of 0.625 mg per kg of body weight of the rat at a concentration of 125 μg / ml aqueous solution to the abdomen of the rat in various patterns.

Referring to FIG. 4, it was found that the hyaluronic acid-upturned nanoparticle conjugate prepared according to Example 2 was specifically transferred deep into the skin.

Therefore, it is considered that up-converting nanoparticles can be specifically transferred deep into the skin by utilizing the presence of hyaluronic acid receptors in a large amount on the skin, and thus it can be utilized for the treatment and diagnosis using light.

Test Example 2: Transmission electron microscopic analysis

Up-converted nanoparticles (a) prepared according to Example 2, silica-coated up-converted nanoparticles (b) prepared in the manufacturing process of Example 4, and hyaluronic acid-converted nanoparticles The result of analysis of the conjugate (c) through a transmission electron microscope is shown in Fig.

Referring to FIG. 5, it was confirmed that the up-converted nanoparticles prepared in Example 2 were uniformly synthesized at a nanosize of 30 to 40 nm. In addition, it was confirmed that the silica-coated up-converted nanoparticles prepared in Example 4 were uniformly coated with silica to a thickness of about 10 nm. The hyaluronic acid-upturned nanoparticle conjugate prepared according to Example 4 could confirm the shape of hyaluronic acid covering the periphery of the up-converted nanoparticles.

Test Example 3: Fluorescence intensity and efficiency analysis

The fluorescence intensity changes of the upconverted nanoparticles (NaYF4: 18% Yb / 2% Er) prepared according to Example 2 according to the laser intensity are shown in FIG. 6 (a) The fluorescence efficiency was measured and shown in Fig. 6 (b).

Referring to FIG. 6, it can be seen that the intensity of the red light of the 670 nm wavelength band of the up-converted nanoparticles prepared according to Example 2 increases as the intensity of the laser increases. In addition, it can be confirmed that the fluorescence intensity of the up-converted nanoparticles prepared according to Example 2 is maintained for a period of 8 months after the synthesis.

Test Example 4: Confirmation of cytotoxicity

The hyaluronic acid-organic carbon carbon bond (HA-OCdot) prepared according to Comparative Example 1 and the hyaluronic acid-upturned nanoparticle conjugate (HA + UCNP) prepared according to Example 4 were immersed in HeLa cell ), Incubated for 24 hours, and cytotoxicity was measured by MTT assay. The results are shown in FIG.

Each conjugate was tested in aqueous solutions at concentrations of 0, 0.0625, 0.125 and 0.25 mg / ml.

Referring to FIG. 7, cell viability exceeding 80% was confirmed in the solution of hyaluronic acid-upturned nanoparticle conjugate prepared according to Example 4 at a high concentration of 250 μg / ml.

Test Example 5: Percutaneous transfer assay

The hyaluronic acid-upturned nanoparticle conjugate (HA + UCNP) and distilled water (Control) prepared according to Example 4 were transdermally transferred to the abdomen of balb / c mice deprived of hair for 30 minutes, Fig. 8 shows the result of observing with a laser using a two-photon microscope.

The hyaluronic acid-upturned nanoparticle conjugate prepared according to Example 4 was injected into a solution with a concentration of 100 μg / ml.

Referring to FIG. 8, it was confirmed that the hyaluronic acid-upturned nanoparticle conjugate prepared according to Example 4 was transferred to the collagen layer.

The scope of the present invention is defined by the appended claims rather than the detailed description and all changes or modifications derived from the meaning and scope of the claims and their equivalents are to be construed as being included within the scope of the present invention do.

Claims (28)

At least one host selected from LiYF ₄ , NaY, NaYF ₄ , NaGdF ₄ and CaF ₃ ;
At least one sensitizer selected from Sm ^{3 +} , Nd ^{3 +} , Dy ^{3 +} , Ho ^{3 +} and Yb ^{3 +} doped in the host; And
At least one activator selected from Er ^{3 +} , Ho ^{3 +} , Tm ^{3 +} and Eu ^{3 +} doped in the host;
Contains up-converted nanoparticles. The method according to claim 1,
Wherein the upconverted nanoparticles are determined by calculating the optimal chemical composition of the lanthanide ion-doped upconverted nanoparticles that absorb at least one wavelength selected from 808, 980, and 1,064 nm through first principle calculation, Nanoparticles. The method according to claim 1,
Wherein the up-converted nanoparticles absorb at least one wavelength selected from 808, 980 and 1,064 nm to emit visible light. The method according to claim 1,
Wherein the sensitizer and the host have a molar ratio of 80:10 to 80:60. An upconverted nanoparticle according to claim 1; And
Hyaluronic acid or derivatives thereof bound to the upconverted nanoparticles;
Containing hyaluronic acid-upconverted nanoparticle conjugate. 6. The method of claim 5,
Wherein the hyaluronic acid-up-converted nanoparticle conjugate further comprises a photosensitizer. The method according to claim 6,
Wherein the photosensitizer is at least one selected from the group consisting of chlorline e6 (Ce6), porphyrin-based photosensitizer and nonporphyrin-based photosensitizer. 8. The method of claim 7,
Wherein the photosensitizer is bound to the up-converted nanoparticle in an amount of 1 to 3 parts by weight based on 1 part by weight of the up-converted nanoparticles. 6. The method of claim 5,
Wherein the derivative of hyaluronic acid is hyaluronic acid substituted with a cystamine having a structure represented by the following formula (1).
[Chemical Formula 1]

In Formula 1,
x and y are each independently an integer selected from 16 to 2,500. 10. The method of claim 9,
Wherein the cystamine is substituted with the substitution ratio of 10 to 21% with respect to the hyaluronic acid. 6. The method of claim 5,
Wherein the weight ratio of the up-converted nanoparticles to hyaluronic acid or a derivative thereof is from 1: 1 to 4: 1. (a) mixing a host precursor, a sensitizer, an activator, and a solvent to prepare a solution; And
(b) heat-treating the solution to produce up-converted nanoparticles;
/ RTI > wherein the nanoparticles are nanoparticles. 13. The method of claim 12,
Wherein the host precursor is selected from the group consisting of YCl ₃ .H ₂ O, YbCl ₃ .H ₂ O, SmCl ₃ .H ₂ O, NdCl ₃ .H ₂ O, GdCl ₃ .H ₂ O, Ca (CF ₃ COO) ₂ , CF ₃ COONa 1 selected from Y (CF ₃ COO) ₃ , Yb (CF ₃ COO) ₃ , Gd (CF ₃ COO) ₃ , Sm (CF ₃ COO) _{3 ,} Nd (CF ₃ COO) _3, NH ₄ F, Characterized in that the nanoparticles comprise at least one species selected from the group consisting of polyaniline and polyaniline. 14. The method of claim 13,
Lt; RTI ID = 0.0 > 1, < / RTI > wherein the solvent comprises octadecene-1. 15. The method of claim 14,
Wherein the solution further comprises at least one selected from the group consisting of oleic acid and oleylamine. 13. The method of claim 12,
Wherein the heat treatment is performed at 250 to 400 < 0 > C. (a) binding the hyaluronic acid or derivative thereof to the upconverted nanoparticles prepared according to claim 12; and (c) binding the hyaluronic acid-upconverted nanoparticle conjugate to the hyaluronic acid. 18. The method of claim 17,
Wherein the binding step comprises the steps of (a ') mixing or dissolving the hyaluronic acid or derivative thereof and the up-converted nanoparticles, and then adding 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDC) is added to the reaction mixture. 19. The method of claim 18,
Wherein the step (a-1) further comprises the step of modifying the surface of the up-converted nanoparticle before the step (a '). 20. The method of claim 19,
The surface of the upconverted nanoparticles may be treated with one or more selected from the group consisting of polyallylamine, polymethylmethacrylate (PMMA), 3-aminopropyltriethoxysilane (APTES), tetraethylorthosilicate (TEOS) (DOPA), and cetyltrimethylammonium bromide (CTAB). The method for producing a hyaluronic acid-upturned nanoparticle conjugate according to claim 1, wherein the modified hyaluronic acid-upturned nanoparticle conjugate is modified with at least one selected from dihydroxyphenylalanine (DOPA) and cetyltrimethylammonium bromide (CTAB). A composition for photogenetics applicable to photogenetics comprising the hyaluronic acid-upturned nanoparticle conjugate according to claim 5 as an active ingredient. 22. The method of claim 21,
Wherein the composition for photogenerectomy is used for controlling neurons using a laser of at least one wavelength selected from 808, 980 and 1,064 nm. A composition for photodynamic therapy comprising the hyaluronic acid-upturned nanoparticle conjugate according to claim 5 as an active ingredient. 24. The method of claim 23,
Wherein the composition for photodynamic therapy is used for treating skin diseases or cancer. 25. The method of claim 24,
Wherein the composition for photodynamic therapy is a patch, a depot, or a external preparation. A non-invasive body light source material delivery system for transdermal delivery of a hyaluronic acid-upturned nanoparticle conjugate according to claim 5. 27. The method of claim 26,
Wherein the non-invasive in-vivo light source material delivery system is used for the treatment and diagnosis of cancer, skin diseases and eye diseases. 28. The method of claim 27,
Wherein the non-invasive in-vivo light source material delivery system is used in a fluorescent tattoo.

Images